Suppr超能文献

口服中药作为晚期非小细胞肺癌化疗后的维持治疗:一项系统评价和荟萃分析。

Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

作者信息

Wang Q, Wang Q, Wang S F, Jiao L J, Zhang R X, Zhong Y, Zhang J, Xu L

机构信息

Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine.

Department of Oncology, Shanghai Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine.

出版信息

Curr Oncol. 2017 Aug;24(4):e269-e276. doi: 10.3747/co.24.3561. Epub 2017 Aug 31.

Abstract

BACKGROUND

The concept of maintenance therapy in cancer treatment is currently under debate because of modest survival benefits, added toxicity, economic considerations, and quality-of-life concerns. Traditional Chinese Medicine (tcm) is widely used in China for cancer patients, offering the advantages of low toxicity and enhancement of quality of life. However, no systematic reviews or meta-analyses have assessed the role of tcm as maintenance treatment for non-small-cell lung carcinoma.

METHODS

We searched the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, PubMed, embase, and the Cochrane Library databases for all eligible studies. The endpoints were overall survival (os), progression-free survival (pfs), the 1-year and 2-year survival rates, and performance status. Our meta-analysis used a fixed-effects model and a random-effects model for heterogeneity in the Stata software application (version 11.0: StataCorp LP, College Station, TX, U.S.A.), with the results expressed as hazard ratios (hrs) or risk ratios (rrs), with their corresponding 95% confidence intervals (95% cis).

RESULTS

Sixteen randomized studies representing 1150 patients met the inclusion criteria. Compared with best supportive care, observation, or placebo, tcm as maintenance treatment was associated with a significant increase in os (hr: 0.49; 95% ci: 0.35 to 0.68; < 0.001), pfs (hr: 0.66; 95% ci: 0.51 to 0.84; = 0.001), and 2-year survival rate (rr: 0.63; 95% ci: 0.44 to 0.92, = 0.017), and a significant improvement in performance status (rr: 0.68; 95% ci: 0.61 to 0.75; < 0.001).

CONCLUSIONS

For patients who show non-progression-including stable disease, partial response, or complete response-after first-line chemotherapy, including those with poor quality of life, oral Chinese herbal medicine can be considered an efficient and safe maintenance therapy strategy.

摘要

背景

由于生存获益有限、毒性增加、经济因素以及生活质量问题,癌症治疗中的维持治疗概念目前仍存在争议。中药在中国被广泛应用于癌症患者,具有低毒性和提高生活质量的优势。然而,尚无系统评价或荟萃分析评估中药作为非小细胞肺癌维持治疗的作用。

方法

我们检索了中国生物医学文献数据库、中国知网、PubMed、Embase和Cochrane图书馆数据库,以查找所有符合条件的研究。终点指标为总生存期(OS)、无进展生存期(PFS)、1年和2年生存率以及体能状态。我们的荟萃分析在Stata软件应用程序(版本11.0:美国德克萨斯州大学站StataCorp LP公司)中使用固定效应模型和随机效应模型处理异质性,结果以风险比(HRs)或比值比(RRs)及其相应的95%置信区间(95% CIs)表示。

结果

16项随机研究共1150例患者符合纳入标准。与最佳支持治疗、观察或安慰剂相比,中药作为维持治疗可显著提高OS(HR:0.49;95% CI:0.35至0.68;P<0.001)、PFS(HR:0.66;95% CI:0.51至0.84;P = 0.001)和2年生存率(RR:0.63;95% CI:0.44至0.92,P = 0.017),并显著改善体能状态(RR:0.68;95% CI:0.61至0.75;P<0.001)。

结论

对于一线化疗后病情无进展(包括疾病稳定、部分缓解或完全缓解)的患者,包括生活质量较差的患者,口服中药可被视为一种有效且安全的维持治疗策略。

相似文献

引用本文的文献

3
Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms.用于非小细胞肺癌的中药:疗法与作用机制
Chin Herb Med. 2023 Sep 21;15(4):509-515. doi: 10.1016/j.chmed.2023.05.004. eCollection 2023 Oct.

本文引用的文献

1
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
6
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
9
Treatment of non-small cell lung cancer (NSCLC).非小细胞肺癌(NSCLC)的治疗。
J Thorac Dis. 2013 Sep;5 Suppl 4(Suppl 4):S389-96. doi: 10.3978/j.issn.2072-1439.2013.07.10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验